Title : Incretin-based Therapies for Type 2 Diabetes.

Pub. Date : 2008

PMID : 27056542






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Injectable formulations of DPP-4-resistant GLP-1-related peptides (incretin mimetics) that are now in clinical use (exenatide) or undergoing trials (e.g. liraglutide) have been shown to reduce fasting and postprandial glucose and glycosylated hemoglobin (A1C) levels and induce weight loss. Exenatide dipeptidyl peptidase 4 Homo sapiens